세계의 섬유근육통 치료 시장 보고서(2025년)

Fibromyalgia treatment encompasses the use of medications to address fibromyalgia, a multifaceted and persistent medical condition primarily characterized by widespread and often debilitating musculoskeletal pain, coupled with a range of other symptoms. The objective of fibromyalgia treatment is to mitigate the severity of the condition and effectively manage the associated symptoms and complications.

The primary categories of fibromyalgia treatment involve symptomatic treatment and targeted treatment. Symptomatic treatment, also referred to as palliative or supportive care, is geared towards addressing individual symptoms and enhancing the overall quality of life for patients. Various drug classes, including antidepressants, antiepileptics, muscle relaxants, analgesics, and others, are available and distributed through diverse channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The fibromyalgia treatment market research report is one of a series of new reports from The Business Research Company that provides fibromyalgia treatment market statistics, including fibromyalgia treatment industry global market size, regional shares, competitors with a fibromyalgia treatment market share, detailed fibromyalgia treatment market segments, market trends and opportunities and any further data you may need to thrive in the fibromyalgia treatment industry. This fibromyalgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fibromyalgia treatment market size has grown steadily in recent years. It will grow from $2.79 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to increasing prevalence of fibromyalgia, growing awareness about fibromyalgia, government initiatives, rising disposable incomes.

The fibromyalgia treatment market size is expected to see steady growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to growing geriatric population, rising healthcare expenditure, rising occurrence of musculoskeletal disorders, increasing research and development activities to develop better treatment. Major trends in the forecast period include advancements in treatment options, strategic collaborations, advancements in integration of technology, innovative treatments.

The forecast of 4.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. pain management by inflating prices of duloxetine formulations and transcutaneous electrical nerve stimulation (TENS) units developed in India and Taiwan, resulting in reduced symptom control and higher rheumatology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The fibromyalgia market is poised for growth due to increasing government actions and initiatives focused on musculoskeletal health. These government actions encompass a range of policies and programs aimed at improving the well-being of individuals affected by musculoskeletal conditions. For example, in 2022, Musculoskeletal Australia, an organization based in Australia, reported that the Australian government launched the "Own Your Health" initiative. This four-year initiative is dedicated to promoting self-care and supporting individuals dealing with musculoskeletal conditions. Hence, the growing emphasis on musculoskeletal health through government initiatives is a driving force behind the expansion of the fibromyalgia market.

The growth of the fibromyalgia treatment market is significantly influenced by the expanding aging population. This demographic shift is characterized by a rising percentage of elderly individuals within society or a given population. The aging population is particularly relevant to the fibromyalgia treatment market as older individuals are more prone to developing fibromyalgia, and they often face more severe symptoms due to age-related factors. For instance, the United Nations Department of Economic and Social Affairs reported in July 2022 that the global population's proportion aged 65 and older is projected to increase from 10% in 2022 to 16% by 2050. Consequently, the growing aging population is a key driver behind the expansion of the fibromyalgia treatment market.

Prominent companies within the fibromyalgia treatment market are prioritizing the development of cutting-edge solutions, such as microchip technology, to maintain their competitive edge in the industry. Proprietary microchip technology is a specific category that harnesses the potential of microchips to deliver precise and targeted nerve stimulation, thereby alleviating symptoms associated with fibromyalgia. Notably, in November 2022, NeuroMetrix Inc., a US-based medical equipment manufacturer, introduced the Quell Fibromyalgia device as part of its Pathfinder Program, presenting a groundbreaking solution for managing fibromyalgia symptoms. Distinguished as the first and only medical device sanctioned by the U.S. Food and Drug Administration (FDA) for mitigating fibromyalgia symptoms, the Quell Fibromyalgia device employs transcutaneous electrical nerve stimulation (TENS). This device leverages proprietary microchip technology to administer accurate, high-intensity nerve stimulation in a compact, wearable design, optimized through position and motion sensing.

In April 2023, the U.S.-based telemedicine company XRHealth merged with Spain-based VR treatment solutions provider Amelia Virtual Care, operating under the XRHealth brand. This merger marks the unification of XRHealth and Amelia Virtual Care, creating a synergistic entity that allows the two companies to leverage their expertise, technologies, and resources. The collaboration integrates XRHealth's immersive and augmented reality technology with Amelia Virtual Care's extensive virtual reality software designed for mental health professionals.

Major companies operating in the fibromyalgia treatment market are Pfizer Inc., Johnson and Johnson Services Inc., Roche Holding AG, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Endo International PLC, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Lupin Limited.

North America was the largest region in the fibromyalgia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibromyalgia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibromyalgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibromyalgia treatment market consists of revenues earned by providing medical diagnosis and evaluation, personalized treatment planning, medication management, pain management clinics and physical therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The fibromyalgia treatment market also includes sales of pain relievers, sleeping aids and anti-anxiety medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibromyalgia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibromyalgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fibromyalgia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The fibromyalgia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Symptomatic Treatment; Targeted Treatment
• 2) By Drug Class: Antidepressants; Antiepileptics; Muscle Relaxants; Analgesics; Other Drugs
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Symptomatic Treatment: Pain Relievers; Antidepressants; Anti-seizure Medications; Sleep Aids; Physical Therapy
• 2) By Targeted Treatment: Cognitive Behavioral Therapy (CBT); Lifestyle Modifications; Complementary Therapies; Medications Targeting Specific Symptoms
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Services Inc.; Roche Holding AG; AbbVie Inc.; Novartis AG; Sanofi S.A.; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Eli Lilly and Company; Amgen Inc.; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Mylan N.V.; Astellas Pharma Inc.; Biogen Inc.; Daiichi Sankyo Co. Ltd.; Boehringer Ingelheim International GmbH; Sun Pharmaceutical Industries Ltd.; Horizon Therapeutics plc; Endo International plc; Amneal Pharmaceuticals Inc.; Zydus Lifesciences Limited; Lupin Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fibromyalgia Treatment Market Characteristics

3. Fibromyalgia Treatment Market Trends And Strategies

4. Fibromyalgia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Fibromyalgia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fibromyalgia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fibromyalgia Treatment Market Growth Rate Analysis
• 5.4. Global Fibromyalgia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fibromyalgia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fibromyalgia Treatment Total Addressable Market (TAM)

6. Fibromyalgia Treatment Market Segmentation

• 6.1. Global Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic Treatment
• Targeted Treatment
• 6.2. Global Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants
• Antiepileptics
• Muscle Relaxants
• Analgesics
• Other Drugs
• 6.3. Global Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Fibromyalgia Treatment Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain Relievers
• Antidepressants
• Anti-seizure Medications
• Sleep Aids
• Physical Therapy
• 6.5. Global Fibromyalgia Treatment Market, Sub-Segmentation Of Targeted Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Behavioral Therapy (CBT)
• Lifestyle Modifications
• Complementary Therapies
• Medications Targeting Specific Symptoms

7. Fibromyalgia Treatment Market Regional And Country Analysis

• 7.1. Global Fibromyalgia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fibromyalgia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fibromyalgia Treatment Market

• 8.1. Asia-Pacific Fibromyalgia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fibromyalgia Treatment Market

• 9.1. China Fibromyalgia Treatment Market Overview
• 9.2. China Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fibromyalgia Treatment Market

• 10.1. India Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fibromyalgia Treatment Market

• 11.1. Japan Fibromyalgia Treatment Market Overview
• 11.2. Japan Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fibromyalgia Treatment Market

• 12.1. Australia Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fibromyalgia Treatment Market

• 13.1. Indonesia Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fibromyalgia Treatment Market

• 14.1. South Korea Fibromyalgia Treatment Market Overview
• 14.2. South Korea Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fibromyalgia Treatment Market

• 15.1. Western Europe Fibromyalgia Treatment Market Overview
• 15.2. Western Europe Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fibromyalgia Treatment Market

• 16.1. UK Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fibromyalgia Treatment Market

• 17.1. Germany Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fibromyalgia Treatment Market

• 18.1. France Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fibromyalgia Treatment Market

• 19.1. Italy Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fibromyalgia Treatment Market

• 20.1. Spain Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fibromyalgia Treatment Market

• 21.1. Eastern Europe Fibromyalgia Treatment Market Overview
• 21.2. Eastern Europe Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fibromyalgia Treatment Market

• 22.1. Russia Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fibromyalgia Treatment Market

• 23.1. North America Fibromyalgia Treatment Market Overview
• 23.2. North America Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fibromyalgia Treatment Market

• 24.1. USA Fibromyalgia Treatment Market Overview
• 24.2. USA Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fibromyalgia Treatment Market

• 25.1. Canada Fibromyalgia Treatment Market Overview
• 25.2. Canada Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fibromyalgia Treatment Market

• 26.1. South America Fibromyalgia Treatment Market Overview
• 26.2. South America Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fibromyalgia Treatment Market

• 27.1. Brazil Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fibromyalgia Treatment Market

• 28.1. Middle East Fibromyalgia Treatment Market Overview
• 28.2. Middle East Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fibromyalgia Treatment Market

• 29.1. Africa Fibromyalgia Treatment Market Overview
• 29.2. Africa Fibromyalgia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fibromyalgia Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fibromyalgia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fibromyalgia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Fibromyalgia Treatment Market Competitive Landscape
• 30.2. Fibromyalgia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Fibromyalgia Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. GlaxoSmithKline plc
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Viatris Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Mylan N.V.
• 31.11. Astellas Pharma Inc.
• 31.12. Biogen Inc.
• 31.13. Daiichi Sankyo Co. Ltd.
• 31.14. Boehringer Ingelheim International GmbH
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Fibromyalgia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibromyalgia Treatment Market

34. Recent Developments In The Fibromyalgia Treatment Market

35. Fibromyalgia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Fibromyalgia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fibromyalgia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fibromyalgia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer